Filing Details

Accession Number:
0000899243-22-030087
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-08-30 17:00:13
Reporting Period:
2022-08-29
Accepted Time:
2022-08-30 17:00:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1701108 Spero Therapeutics Inc. SPRO Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1782817 Sath Shukla C/O Spero Therapeutics, Inc.
675 Massachusetts Avenue, 14Th Floor
Cambridge MA 02139
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-08-29 6,017 $0.89 56,064 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. The reported transaction is a sale of common stock pursuant to a preexisting 10b5-1 plan upon the vesting on August 26, 2022 of a portion of restricted stock units ("RSUs") granted to the Reporting Person on August 26, 2021.
  2. Represents the weighted average sales price per share. The shares sold at prices ranging from $0.8839 to $0.9002 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
  3. Consists of RSUs. Each RSU represents the right to receive one share of common stock upon vesting. 18,050 of the RSUs vest in three equal annual installments beginning on August 26, 2023 and 38,014 of the RSUs vest in four equal annual installments beginning on February 1, 2023, in each case subject to the Reporting Person's continued service through the applicable vesting date.